Efgartigimod Builds a Pediatric Track Record in Myasthenia Gravis
At AAN Annual Meeting 2026, ADAPT Jr showed efgartigimod alfa delivered durable adolescent gMG improvements, with 80% achieving minimal symptom expression by cycle two and consistent responses.
The skinny
The skinny isn't ready yet — notes appear once the transcript is processed.